Find and Pitch Jounalists, Get Your Story Covered

Tags: Addiction health addiction | drug development | opioids | Pharmaceuticals | public health | STAT Breakthrough Summit art history drug addiction

	Profile	Recent Articles on Subject
1	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Up and down the ladder: The latest comings and goings - 6 days ago STAT+: Pharmalittle: We’re reading about Bavarian Nordic’s mpox shot, a crackdown on Ozempic prescribing and more - 6 days ago STAT+: Pharmalittle: We’re reading about Moderna R&D cuts, Lilly plant investments and more - 7 days ago STAT+: Up and down the ladder: The latest comings and goings - 27 days ago STAT+: Pharmalittle: We’re reading about Zepbound trial results, an Alnylam heart drug, and more - about 1 month ago STAT+: Up and down the ladder: The latest comings and goings - about 1 month ago STAT+: Up and down the ladder: The latest comings and goings - about 1 month ago STAT+: Pharmalittle: We’re reading about Roche obesity drug data, fallout from the Menendez verdict, and more - 2 months ago STAT+: Up and down the ladder: The latest comings and goings - 2 months ago STAT+: Up and down the ladder: The latest comings and goings - 3 months ago STAT+: Pharmalittle: We’re reading about Sanders dogging Novo Nordisk, Teva patents, and more - 3 months ago STAT+: Up and down the ladder: The latest comings and goings - 5 months ago STAT+: Pharmalittle: We’re reading about an Amgen obesity drug, a Senate bill on shortages, and more - 5 months ago STAT+: Up and down the ladder: The latest comings and goings - 5 months ago STAT+: Pharmalittle: We’re reading about biotech startups, Pfizer’s RSV vaccine, and more - 5 months ago STAT+: Up and down the ladder: The latest comings and goings - 6 months ago STAT+: Pharmalittle: We’re reading about a European probe into vaccine talks; net drug prices falling, and more - 6 months ago STAT+: Up and down the ladder: The latest comings and goings - 6 months ago STAT+: Pharmalittle: We’re reading about a Lilly obesity-drug ad, a $35 cap on inhalers, and more - 7 months ago STAT+: Oregon suspends a portion of its drug transparency law found to be unconstitutional - 7 months ago STAT+: Pharmalittle: We’re reading about slow uptake of an Alzheimer’s drug, an opioid lawsuit, and more - 7 months ago STAT+: Pharmalittle: We’re reading about Lilly selling drugs directly, UCB leaving BIO, and more news - 9 months ago STAT+: FDA is blasted by advocates for pursuing a deal with data provider that has ties to opioid makers - 9 months ago STAT+: Pharmalittle: FDA approvals rebound, abortion pill orders rise, and more news - 9 months ago
2	Andrew Joseph STAT News Reporter at STAT. Covers health, medicine in Europe. London, England health reportingmedicine	STAT+: A new drug offers a rare option for brain cancer treatment — and inspires hopes for more - 7 days ago
3	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	Summit’s upcoming cancer results, Recursion’s mixed data, and the next big obesity target - 14 days ago
4	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	Summit’s upcoming cancer results, Recursion’s mixed data, and the next big obesity target - 14 days ago Listen: Live! From the STAT Breakthrough Summit East - 6 months ago
5	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	Summit’s upcoming cancer results, Recursion’s mixed data, and the next big obesity target - 14 days ago STAT+: Summit Therapeutics vs. Merck: Prepping for a big lung cancer study reveal - 15 days ago STAT+: Pharmalittle: We’re watching more positive data for Ozempic, a Lilly factory expansion, and more - 4 months ago Listen: Live! From the STAT Breakthrough Summit East - 6 months ago STAT Virtual Event \| Cancer’s Breakthrough Engine - 9 months ago
6	Meghana Keshavan STAT News Biotech nerd and writer @statnews. biotechwriting	STAT+: Rick Doblin, ‘unleashed,’ blasts FDA over Lykos drug rejection and turns to global push for MDMA therapy - about 1 month ago STAT+: More tumult at BIO amid the company’s fourth CEO in four years - 4 months ago
7	Kennedy Ferruggia, Assistant Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Conference Recap: McKesson ideaShare - about 1 month ago McKesson Shares New Initiative to Support Advocacy Efforts for the Pharmacy Profession - 2 months ago
8	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	Autobahn’s road to a breakthrough depression treatment is paved with high-profile investors - about 1 month ago
9	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting	Neuro drugs are still faltering, despite rising investment - about 2 months ago Despite adcomm rejection, Lykos CEO sees future for MDMA drug - 3 months ago After Vyvanse patent loss, Takeda’s neuroscience division looks to enter a new era - 4 months ago Pharma execs sound off on trends and policies they’re tracking in 2024 - 8 months ago PharmaVoice’s Crystal Ball: What’s next in drug innovation and clinical trials - 8 months ago 3 standout digital innovations in pharma this year - 10 months ago
10	Nick Paul Taylor MedTech Dive Top 5 Mario Kart Player. Gaming	FDA finalizes guidance on studying opioid use disorder treatments - 2 months ago Physicians ask FDA to revoke approval of DNA test for opioid addiction - 5 months ago Physicians ask FDA to revoke approval of DNA test for opioid addiction - 5 months ago

Journalists covering addiction | drug development | opioids | Pharmaceuticals | public health | STAT Breakthrough Summit